Biogen (BIIB) Presents New Data on SPINRAZA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq futures slip as tech rally pauses ahead of Warsh's speech
- Oil holds steady, on track for weekly fall on US-Iran talks stalemate
- Dollar heads for weekly gain as Warsh remarks awaited
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
June 30, 2023 4:06 PM EDTInterim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec)
Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatment experience
CAMBRIDGE, Mass., June 30, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced... More
